You can help expand this article with text translated from the corresponding article in Japanese. (January 2024) Click [show] for important translation instructions.
View a machine-translated version of the Japanese article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 1,422 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Japanese Wikipedia article at [[:ja:ゼリア新薬工業]]; see its history for attribution.
You may also add the template {{Translated|ja|ゼリア新薬工業}} to the talk page.
Zeria Shinyaku Kōgyō KK (ゼリア新薬工業株式会社, Zeria Shinyaku Kōgyō Kabushiki-gaisha, Zeria Pharmaceutical Co., Ltd.) is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku[1] executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho (Zeria Pharmaceutical and Cosmetics Laboratory). In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
Zeria holds a leading position within the gastroenterology field in Japan.[3]
In 2019, the pain reliever cream EPATEC (ketoprofen) firstly developed by Nissan Chemical Corporation was revocated authorization of Ministry of Health, Labour and Welfare around the contraindications for women in the third trimester of pregnancy.[4][5][6]
At a facility located in Esbjerg, Denmark the subsidiary ZPD, Zeria Pharmaceuticals Denmark, (formerly Biofac) manufactures Chondroitin Sulfate Sodium.[7] In November 2024 a considerable expansion of the facility was announced.[8]